CATX
Perspective Therapeutics Inc
$
2.190
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.280
Open
2.180
VWAP
2.19
Vol
1.61M
Mkt Cap
162.64M
Low
2.120
Amount
3.53M
EV/EBITDA(TTM)
--
Total Shares
67.41M
EV
-24.40M
EV/OCF(TTM)
--
P/S(TTM)
130.03
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
199.08K
-46.05%
-0.324
+54.29%
199.82K
-14.61%
-0.333
-45.48%
147.00K
-57.02%
-0.351
+40.57%
Estimates Revision
The market is revising Upward the revenue expectations for Perspective Therapeutics, Inc. (CATX) for FY2025, with the revenue forecasts being adjusted by 33% over the past three months. During the same period, the stock price has changed by -40.49%.
Revenue Estimates for FY2025
Revise Upward
+33%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.43%
In Past 3 Month
Stock Price
Go Down
-40.49%
In Past 3 Month
10 Analyst Rating
Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 13.10 USD with a low forecast of 5.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.190
Low
5.00
Averages
13.10
High
18.00
Current: 2.190
Low
5.00
Averages
13.10
High
18.00
Oppenheimer
Oppenheimer
Outperform
maintain
$14
2025-09-15
Reason
Oppenheimer
Oppenheimer
Price Target
$14
2025-09-15
maintain
Outperform
Reason
Oppenheimer reiterated an Outperform rating and $14 price target on Perspective Therapeutics after the firm hosted the company's leadership team for an investor dinner last week. The firm said it came away with increased confidence that the VMT-alpha-NET update at ESMO on October 20 will build on prior results presented this summer at ASCO, while cautioning on setting a bar for response rates given the uncertainty on the length of follow-up for these patients. The 6mCi dose seeks to improve efficacy while preserving the safety margin or VMT-alpha-NET, and management seems confident in 5mCi as a potential go-forward dose in a registrational trial, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$9 -> $12
2025-06-23
Reason
B. Riley
Price Target
$9 -> $12
2025-06-23
maintain
Buy
Reason
B. Riley raised the firm's price target on Perspective Therapeutics to $12 from $9 and keeps a Buy rating on the shares. The firm says sequential positive updates from Perspective drive the higher price target. It now sees an increased probabiliry of success for VMT-alpha-NET to deliver best-in-class efficacy and safety profile.
RBC Capital
Outperform
maintain
$15 -> $16
2025-06-03
Reason
RBC Capital
Price Target
$15 -> $16
2025-06-03
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Perspective Therapeutics to $16 from $15 and keeps an Outperform rating on the shares. The company's recent NET program data update at ASCO shows a competitive ORR - overall response rate - profile while maintaining best in class safety vs. comps even in the context of a small sample size, and the firm believes that profile can be maintained at the second-half update, enabling shares to inflect, the analyst tells investors in a research note.
Truist Securities
Nicole Germino
Strong Buy
Maintains
$21 → $10
2025-04-07
Reason
Truist Securities
Nicole Germino
Price Target
$21 → $10
2025-04-07
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Perspective Therapeutics to $10 from $21 and keeps a Buy rating on the shares. Based on its discussions with the management, the firm has adjusted its model's launch curve timelines for the company's lead assets to reflect the pace of the dose escalation trials for two clinical programs, the analyst tells investors in a research note.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$10
2025-03-31
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$10
2025-03-31
Reiterates
Strong Buy
Reason
Wedbush
David Nierengarten
Buy
Reiterates
$11
2025-03-27
Reason
Wedbush
David Nierengarten
Price Target
$11
2025-03-27
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Perspective Therapeutics Inc (CATX.A) is -1.62, compared to its 5-year average forward P/E of -12.74. For a more detailed relative valuation and DCF analysis to assess Perspective Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.74
Current PE
-1.62
Overvalued PE
5.63
Undervalued PE
-31.11
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.43
Undervalued EV/EBITDA
-18.17
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
215.23
Current PS
2.19
Overvalued PS
722.65
Undervalued PS
-292.20
Financials
Annual
Quarterly
FY2025Q2
YoY :
-44.87%
290.00K
Total Revenue
FY2025Q2
YoY :
+68.54%
-24.04M
Operating Profit
FY2025Q2
YoY :
+96.17%
-22.00M
Net Income after Tax
FY2025Q2
YoY :
+61.11%
-0.29
EPS - Diluted
FY2025Q2
YoY :
+111.91%
-21.02M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
-9.30K
FCF Margin - %
FY2025Q2
YoY :
+255.82%
-7.59K
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 951.27% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
6
316.8K
USD
Months
0-12
1
30.1K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
1.8M
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
1.3M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 951.27% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
6
316.8K
USD
Months
0-12
1
30.1K
USD
Months
CATX News & Events
Events Timeline
2025-10-20 (ET)
2025-10-20
14:08:16
Perspective Therapeutics Declines Following Phase 1/2a Trial Update
2025-10-02 (ET)
2025-10-02
07:05:36
Perspective Therapeutics reports treatment of first patient with PSV359
2025-09-15 (ET)
2025-09-15
07:08:15
Perspective reports first patient administered treatment in Phase 1/2a trial cohort.
Sign Up For More Events
Sign Up For More Events
News
9.0
10-20NewsfilterPerspective Therapeutics Shares Latest Interim Results from Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at ESMO Congress 2025
4.0
10-10BenzingaBTIG Begins Coverage of Perspective Therapeutics with a Buy Rating and Sets Price Target at $14
9.0
10-02NewsfilterPerspective Therapeutics Doses First Patient with PSV359 in Phase 1/2a Study's Second Cohort for FAP-α Positive Solid Tumors
Sign Up For More News
People Also Watch
AMRN
Amarin Corporation PLC
15.710
USD
+0.26%
CRDF
Cardiff Oncology Inc
2.190
USD
-2.67%
BDMD
Baird Medical Investment Holdings Ltd
1.070
USD
-0.93%
FBLA
FB Bancorp Inc
12.070
USD
+0.25%
DOGZ
Dogness International Corp
11.660
USD
-0.15%
NC
NACCO Industries Inc
44.240
USD
+0.94%
CIA
Citizens Inc
6.080
USD
+5.74%
FUND
Sprott Focus Trust Inc
8.170
USD
-0.61%
CRD.B
Crawford & Co
10.480
USD
+3.46%
FLYX
Flyexclusive Inc
3.180
USD
-17.62%
FAQ
What is Perspective Therapeutics Inc (CATX) stock price today?
The current price of CATX is 2.19 USD — it has decreased -1.79 % in the last trading day.
What is Perspective Therapeutics Inc (CATX)'s business?
What is the price predicton of CATX Stock?
What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?
What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Perspective Therapeutics Inc (CATX)'s fundamentals?
How many employees does Perspective Therapeutics Inc (CATX). have?